Boston Scientific posts 1.5% Q3 sales growth but EPS dips; full-year sales forecast raised.

Boston Scientific reported a 1.5% increase in net sales to $5.138 billion for Q3 2026, driven by growth in cardiovascular and MedSurg segments. Despite higher sales, GAAP EPS fell to $0.40 from $0.51 a year ago, with adjusted EPS slightly down at $0.73. The company faced challenges including a cybersecurity incident but remains confident in its long-term strategy and innovation pipeline. For full-year 2026, Boston Scientific raised its net sales growth forecast to about 4.25% and adjusted EPS guidance to $3.16-$3.18, while expecting a slight sales decline in Q4.

Boston Scientific's shares are trading at USD 44.03 on Pluang as of Oct 28, 2026 17:41 WIB, down 2.27% for the day. Despite the company's raised full-year sales growth forecast, investor sentiment appears cautious, reflected in the high sell activity of 99% on the platform. The stock remains well below its 52-week high of USD 104.98, indicating ongoing market wariness.